Granted Patent
B2
US 11,578,331 · App. 16/793,334 · Granted Feb 14, 2023
Combination comprising immunostimulatory oligonucleotides
Inventors:
Matthias Schroff (Berlin, DE); Manuel Schmidt (Berlin, DE); Kerstin Kapp (Berlin, DE); Alfredo Zurlo (Berlin, DE)
Assignee:
Gilead Sciences, Inc.
C12N15/117A61K31/7088A61K39/3955A61K39/39541A61P35/00C07K16/2818C07K16/2827C07K16/30C12N15/111A61K2039/505C12N2310/17C12N2310/32C12N2310/344C12N2310/531C12N2310/532C12N2320/31
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
Claims (4)
1. A linear open-chained non-coding sequence of deoxyribonucleic acids selected from SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.
2. The linear open-chained non-coding sequence of claim 1 , consisting of SEQ ID NO: 7.
3. The linear open-chained non-coding sequence of claim 1 , consisting of SEQ ID NO: 8.
4. The linear open-chained non-coding sequence of claim 1 , consisting of SEQ ID NO: 9.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 23, 2021
From: SCHROFF, MATTHIAS; SCHMIDT, MANUEL; KAPP, KERSTIN; ZURLO, ALFREDO
To: MOLOGEN AG
Reel/Frame 056026/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 28, 2020
From: MOLOGEN AG
To: GILEAD SCIENCES, INC.
Reel/Frame 054858/0419 →
Priority Claims (1)
LU 92821
· Sep 9, 2015
· national
Continuity (3)
Division
15756798